VIMTA LABS
|
VIMTA LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 21.77 | 18.69 | 9.68 | 3.10 |
| CEPS(Rs) | 35.65 | 29.24 | 20.12 | 12.56 |
| DPS(Rs) | 2.00 | 2.00 | 2.00 | - |
| Book NAV/Share(Rs) | 124.46 | 104.52 | 87.92 | 78.19 |
| Tax Rate(%) | 25.89 | 25.78 | 25.00 | 17.23 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 29.83 | 28.85 | 25.14 | 16.57 |
| EBIT Margin(%) | 21.26 | 20.55 | 14.58 | 6.66 |
| Pre Tax Margin(%) | 20.43 | 20.01 | 13.55 | 4.58 |
| PAT Margin (%) | 15.14 | 14.85 | 10.16 | 3.79 |
| Cash Profit Margin (%) | 24.79 | 23.24 | 21.11 | 15.37 |
| Performance Ratios | ||||
| ROA(%) | 14.53 | 14.29 | 8.25 | 2.79 |
| ROE(%) | 19.02 | 19.43 | 11.66 | 3.96 |
| ROCE(%) | 24.59 | 23.92 | 14.25 | 5.84 |
| Asset Turnover(x) | 0.96 | 0.96 | 0.81 | 0.74 |
| Sales/Fixed Asset(x) | 1.09 | 1.12 | 0.99 | 0.89 |
| Working Capital/Sales(x) | 2.99 | 3.63 | 3.72 | 4.72 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.91 | 0.89 | 1.01 | 1.13 |
| Receivable days | 90.00 | 98.63 | 113.74 | 116.83 |
| Inventory Days | 22.94 | 20.99 | 27.52 | 34.60 |
| Payable days | - | - | 1,549.17 | - |
| Valuation Parameters | ||||
| PER(x) | 14.44 | 16.86 | 16.63 | 19.14 |
| PCE(x) | 8.82 | 10.77 | 8.00 | 4.72 |
| Price/Book(x) | 2.52 | 3.01 | 1.83 | 0.76 |
| Yield(%) | 0.64 | 0.63 | 1.24 | - |
| EV/Net Sales(x) | 2.11 | 2.53 | 1.80 | 0.87 |
| EV/Core EBITDA(x) | 6.82 | 8.62 | 7.06 | 4.78 |
| EV/EBIT(x) | 9.91 | 12.32 | 12.36 | 13.09 |
| EV/CE(x) | 1.87 | 2.31 | 1.39 | 0.64 |
| M Cap / Sales | 2.19 | 2.50 | 1.69 | 0.72 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 14.34 | 32.09 | 16.58 | - |
| Core EBITDA Growth(%) | 20.33 | 51.97 | 63.15 | - |
| EBIT Growth(%) | 18.29 | 86.22 | 155.16 | - |
| PAT Growth(%) | 16.55 | 93.09 | 212.71 | - |
| EPS Growth(%) | 16.45 | 93.09 | 212.71 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.05 | 0.08 | 0.16 | 0.19 |
| Current Ratio(x) | 2.86 | 2.60 | 2.05 | 1.67 |
| Quick Ratio(x) | 2.46 | 2.24 | 1.78 | 1.37 |
| Interest Cover(x) | 25.57 | 38.17 | 14.16 | 3.20 |
| Total Debt/Mcap(x) | 0.02 | 0.03 | 0.09 | 0.25 |
Compare Financial Ratios of peers of VIMTA LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VIMTA LABS | ₹1,131.0 Cr | -2.5% | -9.8% | 42% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
VIMTA LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VIMTA LABS | -2.5% |
-9.8% |
42% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
